seratrodast has been researched along with Asthma in 31 studies
Asthma: A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL).
| Excerpt | Relevance | Reference |
|---|---|---|
| " Seratrodast, a TXA2 receptor antagonist, is expected to be a potent antiasthmatic." | 9.10 | The effect of seratrodast on eosinophil cationic protein and symptoms in asthmatics. ( Fukuoka, T; Inase, N; Miyake, S; Tojo, N; Umino, T; Yoshizawa, Y, 2003) |
| "Seratrodast, a potent thromboxane receptor antagonist, is approved in Japan for the treatment of asthma and currently is being developed in the United States." | 9.08 | Population analysis of the pharmacokinetics and pharmacodynamics of seratrodast in patients with mild to moderate asthma. ( Cao, G; Dean, R; Granneman, GR; Killian, A; Locke, C; Samara, E, 1997) |
| "Coupling seratrodast (SD), an antiasthmatic drug, with several different types of NO donors including oxatriazoles, N-hydroxyguanidines and furoxans; evaluating the antiasthmatic effects of coupled compounds by determining their inhibitory activity of guinea pig asthma induced by acetylcholine and histamine; and assessing NO releasing ability." | 7.72 | [Design, synthesis and antiasthmatic activities of NO-donating seratrodast derivatives]. ( Feng, XC; Ji, H; Qiu, SG; Zhang, YH; Zhang, ZG, 2004) |
| "Seratrodast, an antagonist to thromboxane A2 (TXA2) receptors, is not always effective in patients with bronchial asthma." | 7.71 | [Correlation between the clinical effects of Seratrodast and the level of 11-dehydrothromboxane B2 in urine/sputum in bronchial asthma patients]. ( Kotajima, R; Muramatsu, H; Sato, T, 2001) |
| "We examined effects of a thromboxane A2 (TXA2) antagonist seratrodast on airway hyperresponsiveness, exhaled nitric oxide (NO), and eosinophils in induced sputum in 14 asthmatics." | 7.70 | Effects of thromboxane A2 antagonist on airway hyperresponsiveness, exhaled nitric oxide, and induced sputum eosinophils in asthmatics. ( Aizawa, H; Fukuyama, S; Hara, N; Inoue, H; Koto, H; Matsumoto, K; Nakano, H; Yoshida, M, 1998) |
| "Bronchial asthma is a disease defined by reversible airway obstruction, bronchial hyperresponsiveness and inflammation." | 6.41 | Thromboxane A2 inhibition: therapeutic potential in bronchial asthma. ( Benoit, P; de Leval, X; Delarge, J; Dogné, JM; Masereel, B, 2002) |
| " Seratrodast, a TXA2 receptor antagonist, is expected to be a potent antiasthmatic." | 5.10 | The effect of seratrodast on eosinophil cationic protein and symptoms in asthmatics. ( Fukuoka, T; Inase, N; Miyake, S; Tojo, N; Umino, T; Yoshizawa, Y, 2003) |
| "beta-adrenoreceptor blockers such as propranolol provoke bronchoconstriction only in asthmatic patients." | 5.09 | Effect of leukotriene and thromboxane antagonist on propranolol-induced bronchoconstriction. ( Abo, M; Fujimura, M; Hashimoto, T; Ishiura, Y; Kamio, Y; Matsuda, T; Myou, S, 1999) |
| "To determine the effects of a specific thromboxane A(2) (TxA(2)) receptor antagonist, seratrodast, on asthma control and airway secretions." | 5.09 | Effect of a thromboxane A(2) antagonist on sputum production and its physicochemical properties in patients with mild to moderate asthma. ( Isono, K; Kondo, M; Nagai, A; Nagano, Y; Nakata, J; Tamaoki, J, 2000) |
| "Seratrodast, a potent thromboxane receptor antagonist, is approved in Japan for the treatment of asthma and currently is being developed in the United States." | 5.08 | Population analysis of the pharmacokinetics and pharmacodynamics of seratrodast in patients with mild to moderate asthma. ( Cao, G; Dean, R; Granneman, GR; Killian, A; Locke, C; Samara, E, 1997) |
| "Thromboxane A2 (TxA2) plays an important role in asthma." | 4.81 | [Thromboxane A2 synthase inhibitor and receptor antagonist]. ( Adachi, M; Minoguchi, K, 2001) |
| "Coupling seratrodast (SD), an antiasthmatic drug, with several different types of NO donors including oxatriazoles, N-hydroxyguanidines and furoxans; evaluating the antiasthmatic effects of coupled compounds by determining their inhibitory activity of guinea pig asthma induced by acetylcholine and histamine; and assessing NO releasing ability." | 3.72 | [Design, synthesis and antiasthmatic activities of NO-donating seratrodast derivatives]. ( Feng, XC; Ji, H; Qiu, SG; Zhang, YH; Zhang, ZG, 2004) |
| "Seratrodast, an antagonist to thromboxane A2 (TXA2) receptors, is not always effective in patients with bronchial asthma." | 3.71 | [Correlation between the clinical effects of Seratrodast and the level of 11-dehydrothromboxane B2 in urine/sputum in bronchial asthma patients]. ( Kotajima, R; Muramatsu, H; Sato, T, 2001) |
| "We examined effects of a thromboxane A2 (TXA2) antagonist seratrodast on airway hyperresponsiveness, exhaled nitric oxide (NO), and eosinophils in induced sputum in 14 asthmatics." | 3.70 | Effects of thromboxane A2 antagonist on airway hyperresponsiveness, exhaled nitric oxide, and induced sputum eosinophils in asthmatics. ( Aizawa, H; Fukuyama, S; Hara, N; Inoue, H; Koto, H; Matsumoto, K; Nakano, H; Yoshida, M, 1998) |
| "The contributions of histamine, cysteinyl leukotrienes (CysLTs) and thromboxane A2 (TXA2) to the asthmatic responses and the magnitudes of blood and lung eosinophilia at acute and chronic stages of our asthmatic model were comparatively determined." | 3.70 | Repeated antigen inhalations alter chemical mediators that cause asthmatic obstruction in guinea pigs. ( Kohno, S; Nabe, T; Tomioka, H; Yamashita, K, 1999) |
| "The effects of lipid mediator antagonists: the LTD4-receptor antagonist pranlukast, the TXA2-receptor antagonist seratrodast, and the novel dual LTD4- and TXA2-receptor antagonist YM158 (3-[(4-tert-butylthiazol-2-yl)methoxy]-5'-[3-(4-chlorobenzenesu lfonyl) propyl]-2'-(1H-tetrazol-5-ylmethoxy)benzanilide monosodium salt monohydrate) were investigated in animals exhibiting immediate asthmatic response (IAR), late asthmatic response (LAR) and airway hyper-responsiveness (AHR)." | 3.70 | Effect of YM158, a dual lipid mediator antagonist, on immediate and late asthmatic responses, and on airway hyper-responsiveness in guinea pigs. ( Arakida, Y; Honda, K; Miyata, K; Morio, H; Ohga, K; Okada, Y; Suwa, K; Yamada, T; Yokota, M, 2000) |
| "Seratrodast did not suppress IAR or LAR." | 2.69 | Effects of cysteinyl-leukotriene receptor antagonist, thromboxane A2 receptor antagonist, and thromboxane A2 synthetase inhibitor on antigen-induced bronchoconstriction in patients with asthma. ( Asai, S; Kohno, S; Matsuo, N; Matsuse, H; Obase, Y; Shimoda, T, 1998) |
| "COPD (Chronic Obstructive Pulmonary Disease) and bronchial asthma are two severe lung diseases which represent a major problem of world public health." | 2.43 | Prostanoids as pharmacological targets in COPD and asthma. ( Dogné, JM; Masereel, B; Rolin, S, 2006) |
| "Bronchial asthma is a disease defined by reversible airway obstruction, bronchial hyperresponsiveness and inflammation." | 2.41 | Thromboxane A2 inhibition: therapeutic potential in bronchial asthma. ( Benoit, P; de Leval, X; Delarge, J; Dogné, JM; Masereel, B, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (6.45) | 18.7374 |
| 1990's | 17 (54.84) | 18.2507 |
| 2000's | 11 (35.48) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (3.23) | 2.80 |
| Authors | Studies |
|---|---|
| Shiraishi, M | 2 |
| Kato, K | 2 |
| Terao, S | 2 |
| Ashida, Y | 5 |
| Terashita, Z | 1 |
| Kito, G | 1 |
| Powell, WS | 1 |
| Baba, K | 1 |
| Sakakibara, A | 1 |
| Yagi, T | 1 |
| Niwa, S | 1 |
| Wakayama, H | 1 |
| Takagi, K | 1 |
| Fukuoka, T | 1 |
| Miyake, S | 1 |
| Umino, T | 1 |
| Inase, N | 1 |
| Tojo, N | 1 |
| Yoshizawa, Y | 1 |
| Dogné, JM | 2 |
| de Leval, X | 1 |
| Benoit, P | 1 |
| Delarge, J | 1 |
| Masereel, B | 2 |
| Zhang, ZG | 1 |
| Zhang, YH | 1 |
| Ji, H | 1 |
| Qiu, SG | 1 |
| Feng, XC | 1 |
| Rolin, S | 1 |
| Obayashi, O | 1 |
| Ohta, K | 1 |
| Matsumoto, T | 4 |
| Tsukuda, R | 1 |
| Kurokawa, T | 1 |
| Sasada, R | 1 |
| Iwasa, S | 1 |
| Hada, S | 2 |
| Hashizume, M | 2 |
| Nishii, S | 2 |
| Yoshioka, F | 2 |
| Yasunaga, K | 2 |
| Endo, S | 1 |
| Akiyama, K | 1 |
| Kagoshima, M | 2 |
| Tomomatsu, N | 2 |
| Iwahisa, Y | 2 |
| Yamaguchi, S | 2 |
| Kawakami, Y | 2 |
| Terasawa, M | 2 |
| Matsuura, M | 1 |
| Samara, E | 1 |
| Cao, G | 1 |
| Locke, C | 1 |
| Granneman, GR | 1 |
| Dean, R | 1 |
| Killian, A | 1 |
| Obase, Y | 2 |
| Shimoda, T | 2 |
| Matsuo, N | 2 |
| Matsuse, H | 2 |
| Asai, S | 2 |
| Kohno, S | 3 |
| Aizawa, H | 1 |
| Inoue, H | 1 |
| Nakano, H | 1 |
| Matsumoto, K | 1 |
| Yoshida, M | 1 |
| Fukuyama, S | 1 |
| Koto, H | 1 |
| Hara, N | 1 |
| Fukushima, C | 1 |
| Takao, A | 1 |
| Ayabe, H | 1 |
| Hoshino, M | 1 |
| Sim, J | 1 |
| Shimizu, K | 1 |
| Nakayama, H | 1 |
| Koya, A | 1 |
| Yamashita, K | 1 |
| Nabe, T | 1 |
| Tomioka, H | 1 |
| Fujimura, M | 2 |
| Abo, M | 1 |
| Kamio, Y | 1 |
| Myou, S | 1 |
| Ishiura, Y | 1 |
| Hashimoto, T | 1 |
| Matsuda, T | 2 |
| Tanaka, H | 1 |
| Igarashi, T | 1 |
| Saitoh, T | 1 |
| Teramoto, S | 1 |
| Miyazaki, N | 1 |
| Kaneko, S | 1 |
| Ohmichi, M | 1 |
| Abe, S | 1 |
| Arakida, Y | 2 |
| Ohga, K | 2 |
| Suwa, K | 2 |
| Okada, Y | 2 |
| Morio, H | 2 |
| Yokota, M | 2 |
| Miyata, K | 1 |
| Yamada, T | 2 |
| Honda, K | 1 |
| Tamaoki, J | 1 |
| Kondo, M | 1 |
| Nakata, J | 1 |
| Nagano, Y | 1 |
| Isono, K | 1 |
| Nagai, A | 1 |
| Muramatsu, H | 1 |
| Kotajima, R | 1 |
| Sato, T | 1 |
| Minoguchi, K | 1 |
| Adachi, M | 1 |
| Sakamoto, S | 1 |
| Saito, M | 1 |
| Miyake, Y | 1 |
| Kuriki, H | 2 |
| Saijo, T | 1 |
| Kurokawa, D | 1 |
6 reviews available for seratrodast and Asthma
| Article | Year |
|---|---|
Eicosanoid receptors as therapeutic targets for asthma.
Topics: Acetates; Animals; Anti-Asthmatic Agents; Anti-Inflammatory Agents; Asthma; Benzoquinones; Biomarker | 2021 |
Thromboxane A2 inhibition: therapeutic potential in bronchial asthma.
Topics: Anti-Asthmatic Agents; Asthma; Benzoquinones; Carbazoles; Heptanoic Acids; Humans; Methacrylates; Mo | 2002 |
Prostanoids as pharmacological targets in COPD and asthma.
Topics: Animals; Asthma; Benzoquinones; Carbazoles; Enzyme Inhibitors; F2-Isoprostanes; Heptanoic Acids; Hum | 2006 |
[Adverse effects of thromboxane receptor antagonists and synthase inhibitors].
Topics: Adult; Aged; Aged, 80 and over; Anti-Allergic Agents; Asthma; Benzoquinones; Chemical and Drug Induc | 2007 |
[Thromboxane A2 receptor antagonist in asthma therapy].
Topics: Asthma; Benzoquinones; Bridged Bicyclo Compounds; Bronchi; Bronchial Hyperreactivity; Carbazoles; Fa | 1996 |
[Thromboxane A2 synthase inhibitor and receptor antagonist].
Topics: Asthma; Benzoquinones; Bronchi; Bronchial Hyperreactivity; Eosinophils; Heptanoic Acids; Humans; Met | 2001 |
9 trials available for seratrodast and Asthma
| Article | Year |
|---|---|
Long-term observations of the clinical course after step down of corticosteroid inhalation therapy in adult chronic asthmatics: correlation with serum levels of eosinophil cationic protein.
Topics: Adult; Aged; Analysis of Variance; Asthma; Beclomethasone; Benzoquinones; Blood Proteins; Chromones; | 2002 |
The effect of seratrodast on eosinophil cationic protein and symptoms in asthmatics.
Topics: Adult; Anti-Asthmatic Agents; Asthma; Benzoquinones; Blood Proteins; Bronchial Hyperreactivity; Cros | 2003 |
Population analysis of the pharmacokinetics and pharmacodynamics of seratrodast in patients with mild to moderate asthma.
Topics: Adult; Aged; Anti-Asthmatic Agents; Asthma; Benzoquinones; Double-Blind Method; Female; Forced Expir | 1997 |
Effects of cysteinyl-leukotriene receptor antagonist, thromboxane A2 receptor antagonist, and thromboxane A2 synthetase inhibitor on antigen-induced bronchoconstriction in patients with asthma.
Topics: Administration, Oral; Adult; Anti-Asthmatic Agents; Antigens; Asthma; Benzoquinones; Blood Proteins; | 1998 |
Effect of AA-2414, a thromboxane A2 receptor antagonist, on airway inflammation in subjects with asthma.
Topics: Adolescent; Adult; Anti-Asthmatic Agents; Asthma; Benzoquinones; Biopsy; Bronchi; Bronchial Hyperrea | 1999 |
Effect of leukotriene and thromboxane antagonist on propranolol-induced bronchoconstriction.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Asthma; Benzoquinones; Bronchoconstriction; Chromones; Dou | 1999 |
Can urinary eicosanoids be a potential predictive marker of clinical response to thromboxane A2 receptor antagonist in asthmatic patients?
Topics: 6-Ketoprostaglandin F1 alpha; Adult; Aged; Anti-Asthmatic Agents; Asthma; Benzoquinones; Creatinine; | 1999 |
Effect of a thromboxane A(2) antagonist on sputum production and its physicochemical properties in patients with mild to moderate asthma.
Topics: Adult; Aged; Anti-Asthmatic Agents; Asthma; Benzoquinones; Double-Blind Method; Heptanoic Acids; Hum | 2000 |
Effect of a thromboxane A2 receptor antagonist (AA-2414) on bronchial hyperresponsiveness to methacholine in subjects with asthma.
Topics: Adult; Aged; Asthma; Benzoquinones; Bronchi; Dose-Response Relationship, Drug; Drug Synergism; Femal | 1991 |
16 other studies available for seratrodast and Asthma
| Article | Year |
|---|---|
Quinones. 4. Novel eicosanoid antagonists: synthesis and pharmacological evaluation.
Topics: Animals; Arachidonic Acids; Asthma; Benzoquinones; Bronchi; Bronchial Provocation Tests; Chemical Ph | 1989 |
[Design, synthesis and antiasthmatic activities of NO-donating seratrodast derivatives].
Topics: Acetylcholine; Animals; Anti-Asthmatic Agents; Asthma; Benzoquinones; Guanidines; Guinea Pigs; Hepta | 2004 |
Pharmacological modulation of immediate and late airway response and leukocyte infiltration in the guinea pig.
Topics: Acetylcholine; Airway Resistance; Animals; Antibodies; Asthma; Benzoquinones; Bronchoalveolar Lavage | 1994 |
Antagonism of the human thromboxane A2 receptor by an anti-asthmatic agent AA-2414.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Animals; Asthma; Benzoquinones; | 1994 |
[Study on the inhibitory effect of AA-2414 on platelet aggregation and its clinical effect in asthmatic patients].
Topics: Adult; Aged; Asthma; Benzoquinones; Female; Heptanoic Acids; Humans; In Vitro Techniques; Male; Midd | 1993 |
Effects of Y-24180, a long-acting and potent antagonist to platelet-activating factor, on immediate asthmatic response in guinea pigs.
Topics: Animals; Anti-Asthmatic Agents; Asthma; Azepines; Benzoquinones; Bronchodilator Agents; Chromones; D | 1997 |
Suppressive effects of Y-24180, a receptor antagonist to platelet activating factor (PAF), on antigen-induced asthmatic responses in guinea pigs.
Topics: Administration, Oral; Aerosols; Animals; Anti-Allergic Agents; Anti-Asthmatic Agents; Asthma; Azepin | 1997 |
Effects of thromboxane A2 antagonist on airway hyperresponsiveness, exhaled nitric oxide, and induced sputum eosinophils in asthmatics.
Topics: Anti-Asthmatic Agents; Asthma; Benzoquinones; Bronchial Hyperreactivity; Eosinophils; Female; Forced | 1998 |
In vitro responses to antigen stimulation: comparison between human lung parenchyma resected from asthmatic patients and non-asthmatic patients.
Topics: Aged; Airway Resistance; Animals; Antigens; Ascaris; Asthma; Benzoquinones; Dinoprost; Dogs; Female; | 1999 |
Repeated antigen inhalations alter chemical mediators that cause asthmatic obstruction in guinea pigs.
Topics: Administration, Inhalation; Airway Obstruction; Aluminum Hydroxide; Animals; Antigens; Asthma; Benzo | 1999 |
Effect of YM158, a dual lipid mediator antagonist, on immediate and late asthmatic responses, and on airway hyper-responsiveness in guinea pigs.
Topics: Acetylcholine; Airway Resistance; Animals; Anti-Asthmatic Agents; Antigens; Asthma; Benzoquinones; B | 2000 |
Effect of combined leukotriene D(4) and thromboxane A(2) receptor antagonist on mediator-controlled resistance in guinea pigs.
Topics: Administration, Oral; Airway Resistance; Animals; Anti-Asthmatic Agents; Anti-Inflammatory Agents, N | 2000 |
[Correlation between the clinical effects of Seratrodast and the level of 11-dehydrothromboxane B2 in urine/sputum in bronchial asthma patients].
Topics: Adult; Aged; Anti-Asthmatic Agents; Asthma; Benzoquinones; Female; Heptanoic Acids; Humans; Male; Mi | 2001 |
Effect of the prostaglandin endoperoxide antagonist AA-2414 on experimental allergic asthma.
Topics: Animals; Asthma; Benzoquinones; Bronchoconstriction; Guinea Pigs; Heptanoic Acids; Immunoglobulin G; | 1991 |
[Clinical study on the inhibitory effect of AA-2414 on platelet function in asthmatic patients].
Topics: Administration, Oral; Adolescent; Adult; Aged; Asthma; Benzoquinones; Heptanoic Acids; Humans; Middl | 1990 |
A novel anti-asthmatic quinone derivative, AA-2414 with a potent antagonistic activity against a variety of spasmogenic prostanoids.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Administration, Inhalation; Admi | 1989 |